ALB and uterine corpus sarcoma: The nanoformulation with cross-linked HSA, however, slightlydecreased the cytotoxicity against the tested uterine sarcoma cellline and retained the hypertoxicity to the MDR MES–SA/Dx5 cells,and this carrier did not induce intrinsic cytotoxicity at the appliedconcentrations, unlike the HTP carrier.